There were 2,403 press releases posted in the last 24 hours and 359,120 in the last 365 days.

Introducing RNA Therapeutics 2017 – Agenda Released

RNA Therapeutics 2017

SMi’s 8th annual RNA Therapeutics conference will return to Central London on 22nd and 23rd February 2017 with an exclusive keynote from the MHRA

Pushing the boundaries of 21st century pharmaceuticals through targeted delivery systems
— SMi Group
LONDON, ENGLAND, UNITED KINGDOM, October 3, 2016 /EINPresswire.com/ -- SMi’s Group are delighted to announce the return of RNA Therapeutics set to take place next February in Central London. The agenda for 2017 will feature a mix of case study-led presentations, panel debates, interactive workshops and keynote addresses tailored for an audience of professionals and research scientists looking to develop and commercialise novel RNA therapeutics and delivery systems.

Now in its 8th year, RNA Therapeutics 2017 will showcase new developments through clinical and pre-clinical results in areas such as: messenger RNA-based therapeutics, anti-sense oligonucleotides and new sites for RNA silencing.

Event highlights will include topics on emerging concepts in nanoparticle delivery systems, small activating RNA and 3rd generation antisense technology. The conference will also hone in on under-met areas such as targeted delivery beyond the liver, and offer regulatory guidance on the reporting of clinical data through an exclusive MHRA keynote.

Featured speakers include:

• Nagy Habib, Head of Surgery, Co-Founder, Imperial College Healthcare NHS Trust, MiNA Therapeutics
• John Johnston, Clinical Assessor Biologicals & Biotechnology Unit, MHRA
• Heinrich Haas, Vice President RNA Formulation & Drug Delivery, BioNTech RNA Pharmaceuticals
• Bo Rode Hansen, Global Head of RNA Therapeutics, Roche
• Nicole Meisner-Kober, Senior Investigator, RNA Biology, Novartis Institutes for Biomedical Research
• Steve Hood, Director, Bioimaging, GSK
• David Giljohann, CEO, Exicure
• Shai Erlich, Chief Medical Officer & President USA, Quark Pharmaceuticals Inc
• Amotz Shemi, CEO, Silenseed
• Sanyogitta Puri, Associate Principal Scientist, AstraZeneca

A detailed agenda and full speaker line-up is available at www.therapeutics-rna.com

--- end ---

Contact Information:

For all media enquiries contact Teri Arri on Tel: +44 (0)20 7827 6162 / Email: tarri@smi-online.co.uk
To register for the conference, visit www.pre-filled-syringes.com or contact Fateja Begum on
Tel: +44 (0)20 7827 6184 / Email: fbegum@smi-online.co.uk
To sponsor, speak or exhibit at the conference, contact Alia Malick on Tel: +44 (0)20 7827 6168 /
Email: amalick@smi-online.co.uk

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Teri Arri
SMi Group
2078276000
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.